

Curriculum Vitae Antonio Passaro, MD PhD

PERSONAL DETAILS

Name/surname: Antonio Passaro
Date of Birthday: 7th March 1983
Citizenship: Italy
Phone: +39 – 0257489482
Fax: +39 – 0294379235

Email: antonio.passaro@ieo.it

Marital Status: Married, one child

Work address: Division of Thoracic Oncology, European Institute of Oncology
Via G. Ripamonti, 435, 20141
Milan, [Italy](#)

EDUCATION

Medical Degrees

2008 Degree in Medicine and Surgery with grades 110/110 summa cum laude | Sapienza University of Rome
2014 Board Certification in Medical Oncology with grade 70/70 summa cum laude | Sapienza University of Rome

Science Degrees

2013 Master in Thoracic Oncology (MITHO) with [honor](#)
2018 PhD in Molecular Medicine with honor | Sapienza University of Rome

Fellowship

2010 Fox Chase Cancer Centre, Dep of Medical Oncology, Philadelphia (USA)
2012 Thoracic Oncology-Medical Oncology Division, University Hospital, Parma
2013 1st Oncological Pulmonary Unit San Camillo Hospital, Roma
2014 Division of Thoracic Oncology, European Institute of Oncology, Milan

Medical Oncology Career

2009 – 2012 Dep of Medical Oncology, Policlinico Umberto I, Sapienza University of Rome
2013 1st Oncological Pulmonary Unit, San Camillo Hospital, Roma
2013 – 2017 Fellow, Division of Thoracic Oncology, European Institute of Oncology, Milan
2018 Assistant, Division of Thoracic Oncology, European Institute of Oncology, Milan

MEMBERSHIP OF SOCIETIES

- European Society of Medical Oncology (**ESMO**)
- Italian Association of Medical Oncology (**AIOM**)
- Italian Association of Thoracic Oncology (**AIOT**)
- International Association for the Study of Lung Cancer (**IASLC**)
- European Thoracic Oncology Platform (**ETOP**)

HONOURS AND PRIZES

2011 Winner of EMCTO (European Multidisciplinary Conference in Thoracic Oncology) Travel Grants
2012 Winner of AIOM (Italian Association of Medical Oncology) fellowship for “Young Oncologists 2012”: lung cancer
2012 Winner of “Fondazione Federico Calabresi Grant”, for the best 2012 publication of young oncologist,
2013 Winner of Master in Thoracic Oncology Award
2014 ESMO/IASLC European Lung Cancer Congress travel award
2018 ESMO Leadership Generation Programme award

SCIENTIFIC AND EDITORIAL ASSIGNMENT

2013 to nowadays	Editorial Board Member, Journal of Thoracic Disease (JTD)
2014 to 2015	Editor of Early and locally advanced Disease, European Thoracic Oncology Platform (ETOP)
2015 to 2017	Elected Member of National Young Committee of AIOM (Italian association of Medical Oncology)
2019	Scientific Committee for AIOM Lung Cancer Guideline
2019	ESMO faculty member for the Lung and other Thoracic Tumours faculty group

PEER REVIEWED PUBLICATIONS

1. **Passaro A**, Prelaj A, Bonanno L, Tiseo M, Tuzi A, Proto C, Chiari R, Rocco D, Genova C, Sini C, Cortinovis D, Pilotto S, Landi L, Bennati C, Camerini A, Toschi L, Putzu C, Cerea G, Spitaleri G, Cappuzzo F, de Marinis F.
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations.
Clin Lung Cancer. 2018 Nov 20. pii: S1525-7304(18)30301-2. doi: 10.1016/j.clcc.2018.11.005.
2. **Passaro A**, Stati V, de Marinis F.
Immunotherapy in refractory SCLC: the caterpillar struggling to become a butterfly.
Pulmonology. 2018 Nov - Dec;24(6):321-322. doi: 10.1016/j.pulmoe.2018.12.001. No abstract available.
3. Dieci MV, Massari F, Giusti R, Inno A, Lombardi G, Noto L, **Passaro A**, Pietrantonio F, Spada F, Valente M, Di Maio M, Torri V.
Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM).
ESMO Open. 2018 Oct 21;3(6):e000389
4. Spitaleri G, **Passaro A**, de Marinis F.
Ersartinib (X-396) a novel drug for anaplastic lymphoma kinase-positive non-small cell lung cancer patients: we need smart trials to avoid wasting good bullets.
Chin Clin Oncol. 2018 Oct 15. pii: cco.2018.09.03. doi: 10.21037/cco.2018.09.03
5. Fumagalli C, Guerini-Rocco E, Vacirca D, **Passaro A**, Marinis F, Barberis M
The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy.
Immunotherapy. 2018 Sep;10(12):1041-1045. doi: 10.2217/imt-2018-0027.
6. Fogli S, Polini B, Del Re M, Petrini I, **Passaro A**, Crucitta S, Rofi E, Danesi R.
EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance.
Pharmacogenomics. 2018 Jun 1;19(8):727-740. doi: 10.2217/pgs-2018-0038.
7. **Passaro A**, de Marinis F
Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option.
Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S100-S102. doi: 10.21037/tlcr.2018.02.09
8. Guerini-Rocco E, **Passaro A**, Casadio C, De Luca VM, Guarize J, de Marinis F, Vacirca D, Barberis M.
Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples.
Arch Pathol Lab Med. 2018 Apr;142(4):465-473. doi: 10.5858/arpa.2017-0158-RA.
9. Fumagalli C, Vacirca D, Rappa A, **Passaro A**, Guarize J, Rafaniello P, de Marinis F, Spaggiari L, Casadio C, Viale G, Barberis M, Guerini-Rocco E.
The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
J Clin Pathol. 2018 Sep;71(9):767-773. doi: 10.1136/jclinpath-2018-205032.
10. Del Re M, Arrigoni E, Restante G, **Passaro A**, Rofi E, Crucitta S, De Marinis F, Di Paolo A, Danesi R.
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells.
Stem Cells. 2018 May;36(5):633-640. doi: 10.1002/stem.2787.
11. Metro G, **Passaro A**, Lo Russo G, Bonanno L, Giusti R, Gregorc V, Capelletto E, Martelli O, Cecere FL, Giannarelli D, Luciani A, Bearz A, Tuzi A, Scotti V, Tonini G, Galetta D, Carta A, Soto Parra H, Rebonato A, Morabito A, Chiari R
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Future Oncology, 2017. 10.2217/fon-2017-0441 C _ 2017
12. I Attili, **Passaro A**, Pavan A, Conte PF, de Marinis F, Bonanno L
Combination immunotherapy strategies in advanced Non-Small Cell Lung Cancer (NSCLC): Does biological rationale meet clinical needs?
Critical Reviews in Oncology / Hematology 119 (2017) 30–39. DOI: <http://dx.doi.org/10.1016/j.critrevonc.2017.09.007>
13. **Passaro A**, Prelaj A, Pochesci A, Spitaleri G, Rossi G, Del Signore E, Catania C, de Marinis F
Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.

14. Rampinelli C, Spitaleri G, **Passaro A**, Pochesci A, Ancona E, De Marinis F
Lung Tissue Injury as Atypical Response to Nivolumab in NSCLC.
Am J Respir Crit Care Med. 2017 Sep 14. doi: 10.1164/rccm.201705-0875IM.
15. **Passaro A**, Guerini-Rocco E, Pochesci A, Vacirca D, Spitaleri G, Catania CM, Rappa A, Barberis M, de Marinis F.
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment.
Pharmacol Res. 2017 Mar;117:406-415. doi: 10.1016/j.phrs.2017.01.003.
16. Tuzi A, Bolzacchini E, Suter MB, Giaquinto A, **Passaro A**, Gobba S, Vallini I, Pinotti G.
Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration.
J Thorac Dis. 2017 May;9(Suppl 5):S405-S409. doi: 10.21037/jtd.2017.04.09
17. Marchetti A, Barberis M, Di Lorito A, Pace MV, Di Lisio C, Felicioni L, Guerini-Rocco E, Vingiani A, D'Antuono T, Liberatore M, Filice G, De Luca G, de Marinis F, **Passaro A**, Guetti L, Irtelli L, Crinò L, Mucilli F, Buttitta F.
ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm
JCO Precision Oncology. 2017, DOI: 10.1200/PO.16.00010
18. Imane Chaib, Karachaliou N, Pilotto S, Codony Servat J, Cai A, Drozdowskyj A, Codony Servat C, Yang J, Hu G, Felipe A, Vivanco L, Vergnenegre A, Sanchez JM, Provencio M, de Marinis F, **Passaro A**, Carcereny E, Reguart N, Garcia Campelo C, Teixido C, Sperduti I, Rodriguez S, Lazzari C, Verlicchi A, de Aguirre A, Queralto C, Wei J, Estrada R, de la Bellacasa P, Ramirez JL, Jacobsen K, Ditzel HJ, Santarpia M, Viteri S, Molina MA, Zhou C, Cao P, Ma PC, Bivona TG, Rosell R.
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx014.
19. De Marinis F and **Passaro A**.
Nivolumab in second-line treatment of squamous non-small cell lung cancer
Recenti Prog Med. 2016 Dec;107(12):634-640. doi: 10.1701/2502.26230.
20. **Passaro A**, Lazzari C, Karachaliou N, Spitaleri G, Pochesci A, Catania C, Rosell R, de Marinis F.
Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice.
Onco Targets Ther. 2016 Oct 17;9:6361-6376.
21. **Passaro A**, Pochesci A, Spitaleri G, Catania C, Noverasco C, Del Signore E, de Marinis F.
Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data.
Expert Rev Clin Pharmacol. 2016 Sep 20;1-6. DOI: 10.1080/17512433.2016.1233059
22. Rizzo S, Petrella F, **Passaro A**, de Marinis F, Bellomi M.
Proposals for revisions of the classification of lung cancers with multiple pulmonary sites: the radiologist's, thoracic surgeon's and oncologist's point of view.
J Thorac Dis. 2016 Aug;8(8):E805-8. doi: 10.21037/jtd.2016.07.23.
23. Li Q, Zhan P, Yuan D, Lv T, Krupnick AS, **Passaro A**, Brunelli A, Smeltzer MP, Osarogiagbon RU, Song Y.
Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis.
Transl Lung Cancer Res. 2016 Jun;5(3):258-64. doi: 10.21037/tlcr.2016.06.13.
24. **Passaro A**, Spitaleri G, de Marinis F.
First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?
Expert Rev Anticancer Ther. 2016 Aug;16(8):799-801.
25. Catania C, **Passaro A**, Rocco EG, Spitaleri G, Barberis M, Noverasco C, Signore ED, Travaini L, de Marinis F. Dramatic
Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.
Clin Lung Cancer. 2016 Sep;17(5):e179-e183. doi: 10.1016/j.clcc.2016.05.004.
26. Dama E, Tillhon M, Bertalot G, de Santis F, Troglio F, Pessina S, **Passaro A**, Pece S, de Marinis F, Dell'Orto P, Viale G, Spaggiari L, Di Fiore PP, Bianchi F, Barberis M, Vecchi M.
Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer.
Oncotarget. 2016 May 19. doi: 10.18632/oncotarget.9471.
27. Pochesci A, **Passaro A**, Catania C, Noverasco C, Del Signore E, Spitaleri G, De Marinis F.
Immunotherapy in non-small cell lung cancer: evolution of knowledge and clinical advances.
Recenti Prog Med. 2016 Apr;107(4):186-92.
28. **Passaro A**, Pochesci A, Spitaleri G, Catania C, Noverasco C, Del Signore E, de Marinis F.
Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?
J Thorac Dis. 2016 Mar;8(3):E217-20. doi: 10.21037/jtd.2016.02.21.
29. Bozzetti C, Quaini F, Squadrilli A, Tiseo M, Frati C, Lagrasta C, Azzoni C, Bottarelli L, Galetti M, Belletti S, Gatti R, **Passaro A**, Gradilone A, Cavazzoni A, Alfieri R, Petronini PG, Carubbi C, Pedrazzi G, Nizzoli R, Naldi N, Pinto C, Ardizzoni A.
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture

Method.

PLoS One. 2015 Nov 16;10(11):e014289

30. **Passaro A**, Barberis M, Catania C, S Pessina, F de Marinis
Concomitant ALK translocation and other non-EGFR gene in NSCLC: knowledge in the making.
Ann Oncol. 2015 Mar 19. pii: mdv150.
31. Catania C, Botteri E, Barberis M, Conforti F, Toffalorio F, Marinis FD, Boselli S, Noberasco C, Delmonte A, Spaggiari L, Rotmensz N, **Passaro A**, Bazolli B, Alfieri M, Manzotti M, Fumagalli C, Milani A, T De Pas
Molecular features and clinical outcome of lung malignancies in very young people.
Future Oncol. 2015 Apr;11(8):1211–21. doi: 10.2217/fon.15.10.
32. de Marinis F, Vergnenegre A, **Passaro A**, Dubos-Arvis C, Carcereny E, Drozdowskyj A, Zeaiter A, Perez-Moreno P, Rosell R Erlotinib – associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial. *Future Oncol*. 2015;11(3):421-9. doi: 10.2217/fon.14.269.
33. **Passaro A**, Di Maio M, Del Signore E, Gori B, de Marinis F
Management of non-hematologic toxicities associated with different EGFR TKIs in advanced NSCLC: a comparison analysis.
Clinical Lung Cancer, 2014, Jul;15(4):307-12.
34. de Marinis F and **Passaro A**.
Afatinib-related non-hematologic adverse events: is common evaluation enough for now?
J Clin Oncol. 2014 Mar 10;32(8):864-5.
35. de Marinis F, Catania C, **Passaro A**.
Afatinib in NSCLC harbouring EGFR mutations.
Lancet Oncol 2014 Apr; 15(4) :e148-9.
36. D'Antonio C, **Passaro A**, Gori B, et al. Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A, de Marinis F
Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies.
Ther Adv Med Oncol. 2014 May;6(3):101–114.
37. **Passaro A**, de Marinis F.
Expectations as outcome of effectiveness for patients with metastatic lung cancer.
Ann Palliat Med; 2013 Sep 10. Doi: 10.3978/j.issn.2224-5820.2013.09.01
38. de Marinis F, **Passaro A**, Clarke S.
Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer.
Lung Cancer; 2013 Sep 12. doi:pii: S0169-5002(13)00422-4.
39. **Passaro A**, Gori B, de Marinis F.
Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials.
J Thorac Dis; 2013 Aug;5(4):383-4.
40. **Passaro A**, Fasano M, Bria E, Morgillo F, Alesini D, Pellegrino A, Cantile F, Cortesi E, Ciardiello F.
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?
Lung Cancer; 10.1016/j.lungcan.2013.01.023
41. **Passaro A**, Alesini D, Pochesci A, Cortesi E.
Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.
Anticancer Agents Med Chem; 2012 Nov 5. [Epub ahead of print]
42. **Passaro A**, Cortesi E.
Neoadjuvant EGFR TKIs: toward personalized management in non-small-cell lung cancer.
Transl Lung Cancer Res; Sep 24, 2012. DOI: 10.3978/j.issn.2218-6751.2012.09.1
43. Alesini D, Iacovelli R, Palazzo A, Altavilla A, Risi E, Urbano F, Manai C, **Passaro A**, Magri V, Cortesi E.
Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules.
Oncology. 2013;84(2):92-9. doi: 10.1159/000343821
44. **Passaro A**, Palazzo A, Trenta P, Mancini ML, Morano F, Cortesi E.
Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer.
Curr Med Chem. 2012;19(22):3689-700.
45. **Passaro A**, Trenta P, Conte D, Campennì G, De Benedetto A, Cortesi E.
The Impact of Chemotherapy on the Lymphatic System in Thoracic Oncology.
Thorac Surg Clin. 2012 May;22(2):243–9
46. **Passaro A**, Cortesi E, de Marinis F.
Second-line treatment of non-small cell lung cancer. Chemotherapy or tyrosin kinase inhibitors?
Expert Rev Anticancer Ther. 2011 Oct;11(10):1587-97

SELECTED MEETINGS PAPER

- Rosell R, Karachaliou N, Cui JJ, Chaib I, Berenguer J, Bratch J, Li X, Yang J, Drozdowskyj A, Codony Servat C, Codony Servat J, Giménez-Capitán A, Viteri S, Molina-Vila M, López-Vivanco G, Vergnenegre A, Sánchez-Torres JM, Provencio M, de Marinis F, **Passaro A**, Carcereny E, Reguart N, García Campelo N, Ignatius Ou S, Cardona A, Cao P
P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC.
JTO 2017, Volume 12, Issue 11, Supplement 2, Page S2230
- Rosell R, Karachaliou N, Cui JJ, Chaib I, Berenguer J, Bratch J, Li X, Yang J, Drozdowskyj A, Codony Servat C, Codony Servat J, Giménez-Capitán A, Viteri S, Molina-Vila M, López-Vivanco G, Vergnenegre A, Sánchez-Torres JM, Provencio M, de Marinis F, **Passaro A**, Carcereny E, Reguart N, García Campelo N, Ignatius Ou S, Cardona A, Cao P
TPX-0005 with an EGFR tyrosine kinase inhibitor (TKI) overcomes innate resistance in EGFR mutant NSCLC
JTO 2017, Volume 12, Issue 11, Supplement 2, Page S2230
- Metro G, **Passaro A**, Lorusso G, Bonanno L, Giusti R, Gregorc V, Capelletto E, Martelli O, Cecere FL, Giannarelli D, Luciani A, Bearz A, Tuzi A, Scotti V, Tonini G, Galetta D, Soto Parra HJ, Morabito A, Chiari R
Efficacy of ceritinib administered to patients with crizotinib-refractory, ALK-positive, advanced NSCLC within the Italian compassionate use program. *Annals of Oncology* 2017; 28(suppl_6)
- **Passaro A**, Metro G, Tiseo M, Migliorino MR, Santo A, Sperandi F, Maione P, Puppo G, Grossi F, Soto Parra HJ, Borra G, Roca E, Rocco D, Stasi I, Galetta D, Carta AM, Milella M, Fasola G, Gebbia V, Ferrari S, de Marinis F
ASTRIS, a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC): preliminary analysis of the Italian cohort. *Annals of Oncology*, October 2017; 28(suppl_6)
- Karachaliou N, Imane Chaib I, Cardona A, López-Vivanco G, Vergnenegre A, Sánchez JM, Provencio M, de Marinis F, Passaro A, Carcereny E, Reguart N, García Campelo R, Santarpia M, Viteri S, Molina Vila MA, Li X, Zhou C, Morán T, Ramírez Serrano JL, Bivona T, Ma P, Drozdowskyj A, Cao P, Rosell R,
Co-Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer.
Journal of Thoracic Oncology 2017, 12(1):S1216-S1217
- Mancuso P, **Passaro A**, Labanca V, Gandini S, Spitaleri G, Guerini-Rocco E, Barberis M, Noberasco C, Del Signore E, Pochesci A, Catania C, de marinis F, Bertolini F
Baseline myeloid-derived suppressor cell and eosinophil cell counts predict clinical efficacy in patients with non-small cell lung cancer (NSCLC) treated with nivolumab in second line Abstract 2635
Presented at AACR 2016; published on *Cancer Research* 2017; 77(13 Supplement):2635-2635
- Baseline Peripheral Blood Cell Subsets Associated with Survival Outcomes in Advanced NSCLC Treated with Nivolumab in Second-Line Setting
Passaro A, Mancuso P, Labanca V, Spitaleri G, Guerini-Rocco E, Barberis M, Gandini S, Noberasco C, Del Signore E, Catania C, Pochesci A, Bertolini F, de Marinis F.
JTO 2017, 12(1):S812
- **Passaro A**, Yang JC, Ahn M, Dickgreber NJ, Halmos B, Hirsh V, Hochmair MJ, Levy BP, de Marinis F, Mok T, O'Byrne K, Okamoto I, Schuler M, Sebastian M, Shah R, Tan E, Yamamoto N, Märten A, Wind S, Carbone DP
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
Annals of Oncology, Volume 26, Issue suppl_6, 1 October 2015, Pages vi
- **Passaro A**, Del Signore E, de Marinis F.
Comparative analysis of incidence and trend of non-hematologic toxicities in advanced non-small cell lung cancer patients treated with EGFR TKIs. *Journal of Thoracic Oncology* (2014) 9 (Supplement 9): S7-S52. 10.1097
- **Passaro A**, Gori B, Leone A, Graziano P, de Marinis F.
Clinical implications of rebiopsy in patients with NSCLC harbouring EGFR mutations with acquired resistance to EGFR tyrosine kinase inhibitors.
Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52.
- Bozzetti C, **Passaro A**, Cavazzoni A, Carubbi C, Lagrasta C, Ardizzoni A, Tiseo M.
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung.
Lung Cancer 2013, Suppl1, S1-S76,
- **Passaro A**, Pochesci A, Palleschi M, Pellegrino A, Fabbri MA, Urbano F, Gentile V, Manai C, Pavese I, Cortesi E.
Efficacy and safety of pemetrexed as second-line treatment in elderly patients with advanced non-squamous NSCLC: a retrospective analysis
Journal of Thoracic Oncology, 192P, S70, vol7, n6, Suppl1, 2012
- **Passaro A**, Fasano M, Morgillo F, Pellegrino A, Cantile F, Alesini D, Cortesi E, Ciardiello F.
Erlotinib every other day (EOD): a multicenter observational study.
Tumori 2011, S71, D38 Vol 11, Num 2.
- **Passaro A**, Pellegrino A, Palazzo A, Iacovelli R, Conte D, Truscelli K, Alesini D, Modica D, E. Cortesi.
Long-term survival in unselected patients treated with a personalized schedule with Erlotinib.
Lung Cancer, Feb 2011, iss.71, Supp 2.

- **Passaro A**, Pavese I, Lanzetta G, Di Fonzo C, Mancuso A, Gianni W, Spinelli GP, Madaio R, Lembo A, Martelli O
Cancer pain management in oncological settings. The role of oxycodone: a new option starting strategy therapy?
Annals of Oncology October 2010; 1186P (vol.21, suppl.8)
- Petracca A, Nicolazzo C, Raimondi C, Mazzoli M, **Passaro A**, Iacovelli R, Conte D, Pellegrino A, Trenta P, Cortesi E, Gazzaniga P
Elusion of apoptosis, stemness and drug resistance in circulating tumor cells from colorectal cancer patients
Annals of Oncology July 2010; P1006; (vol.21,suppl.6)
- Petracca A, Nicolazzo C, Palazzo A, Tuzi A, **Passaro A**, Altavilla A, Cortesi E, Naso G, Raimondi C, Gazzaniga P.
Breast cancer resistance to anthracyclines and taxanes under a magnifying lens: emerging role of circulating tumor cells
Annals of Oncology May 2010; 106P (21, suppl 4).
- Mazzoli M, Puglisi M, **Passaro A**, Altavilla A, Truscelli K, Mancini ML, Trenta P, Tuzi A, Conte D, Palazzo A, Iacovelli R, Fabbri MA, Cortesi E.
Tritation with normal release oral morphine in patients with moderate to severe cancer pain
Annals of Oncology 2009 Oct; B82: viii 39.
- Lanzetta G, Pavese I, Mancuso A, Madaio R, **Passaro A**, Di Fonzo C, Cifaldi L, Lembo A, Roberto V, Martelli O.
Oxycodone CR for moderate to severe cancer pain: results of an open-label, multicentre, observational study with special focus on drug tritiation in a regional multicentre experience.
Annals of Oncology 2009 Oct;B29: viii 29
- Mazzoli M, Puglisi M, **Passaro A**, Altavilla A, Cantisani E, Zanon E, Collova` E, Di Fonzo C, Pacetti U, Russo P, Petricola F, Salerno M, Cortesi E
Patient's attitudes towards treatment in advanced cancer: how these are identified from their physician?
Annals of Oncology 2009 Oct; B24: viii 25.
- Palazzo A, Iacovelli R, Mazzoli M, Mancini ML, **Passaro A**, Altavilla A, Conte D, Naso G, Cortesi E
Erlotinib related toxicity in elderly patients affected by non-small cell lung cancer (NSCLC)
Lung Cancer 2009 May; Vol 64 –suppl 1.
- Fabbri MA, Ciprotti M, Trani L, Puglisi M, Pezzoli V, **Passaro A**, Tuzi A, Ferraldeschi R, D'Auria G, Barni S, Naso G
Single centre clinical experience with Fulvestrant in pretreated postmenopausal patients with metastatic breast
Annals of Oncology 2008 Oct; 19: ix87 –ix102
- Rocchi A, Tuzi A, **Passaro A**, Altavilla A, Truscelli K, Naso G, Cortesi E;
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy.
Annals of Oncology 2008 Oct; 19: ix11–ix23

CONFERENCES ATTENDED AS FACULTY/CHAIRMAN

- YTO Young Thoracic Oncologist Meeting: sharing Experience
Milan, 05/apr/2017
- Convegno Nazionale AIOM Giovani: 2017 News in Oncology
Perugia, 07-08/Jul/2017
- XVIII Annual National Meeting AIOM (Italian Association of Medical Oncology)
Rome, 28-30/Oct/2016
- Convegno Nazionale AIOM Giovani: 2016 News in Oncology
Perugia, 08-09/Jul/2016
- Campus in Oncologia
Bologna, 25-26/Jun/2015

INVITED SPEAKER AT INTERNATIONAL MEETING

- 5th International Conference on Thoracic Oncology
Talk: New target in NSCLC: RET
Naples, 23-25/Jun/2016
- International Conference on Immunotherapy and cancers: reality and hopes
Talk: Safety of immune checkpoint inhibitors in NSCLC
Naples, 03/Jun/2015
- 11th Spanish Congress on Lung Cancer
Talk: EGFR TKIs association in first-line setting
Barcelona, 26-27/Nov/2015

INVITED SPEAKER AT NATIONAL MEETING

- National XIX Grandangolo 2017, Un anno di Oncologia
Talk: Neoplasie toraciche - Microcitoma e localmente avanzato (adiuvante, neoadiuvante e terapie integrate)
Genova, 14-16/Dec/2017
- Nivolution on the road
Talk: Overview dei dati CheckMate 017 & 057
Verona, 05/Dec/2017
- Tumori polmonari, evidenze ed esperienze
Talk: Nuovi scenari nella malattia con Driver molecolare – EGFR, dove siamo?
Cremona, 27/Nov/2017
- Best of IASLC WCLC 2017
Talk: Rare thoracic malignancies
Turin, 06/Nov/2017
- Scuola italiana di Immuno Oncologia Toracica
Talk: Interactive case presentation on immunotherapy
Rome, 23/Jun/2017
- YTO Young Thoracic Oncologist Meeting: sharing Experience
Talk: Come sta cambiando il nostro paradigma di trattamento nel NSCLC
Milan, 05/apr/2017
- AIOM-SIAPEC Consensus meeting PD-L1
Talk: un nuovo algoritmo diagnostico nel NSCLC: il ruolo emergente di PD-L1 come biomarcatore
Milan, 04/Apr/2017

- 4nd Corso Multidisciplinare di Oncologia Polmonare
Talk: Gestione terapeutica dei pazienti con mutazione di EGFR
Milan, 30-31/Mar/2017

- AIOM - IMMUNOTERAPIA NEI TUMORI DEL POLMONE E DELL'UROTELIO
Talk: Immunoterapia nel tumore del polmone – i risultati
Rome, 27-28/Mar/2017

- XXVIII Congresso Nazionale SPIGC
Talk: discussant of case presentation of lung cancer
Varese, 22-24/Mar/2017

- Impatti clinici ed economici del nuovo scenario del tumore del polmone
Title: la strategia terapeutica nel tumore del polmone con mutazione di EGFR
Milan, 15/Dec/2016

- L'immunoterapia nel NSCLC: impatto sulla pratica clinica
Title: tossicità immuno-correlate
Olbia, 29/Nov/2016

- Lung Collection 2016
Title: La prima linea di trattamento nel NSCLC con mutazione attivante di EGFR
Milan, 16/Nov/2016

- XVIII Annual National Meeting AIOM (Italian Association of Medical Oncology)
Talk: Educational Lung Cancer Session
Rome, 28-30/Oct/2016

- L'evoluzione del bersaglio molecolare nel paziente NSCLC EGFR+: focus su T790M
Talk Oltre la prima linea, targeting T790M
Milan, 23/Sep/2016

- 2nd Meeting Nazionale Alcase Italia
Talk: The experience of European Institute of Oncology
Milan, 24-25/Sep/2016

- IMAGING ACADEMY: il ruolo dell'immagine nel trattamento del NSCLC
Talk: discussione di situazioni cliniche esemplificative
Milan, 23/Mar and 18/May/2016

- Carcinoma del polmone non microcitoma: quali novità per il 2016?
Talk: Immunoterapia: casi clinici esemplificativi
Verona, 8-9/Apr/2016

- Scuola italiana di Immuno Oncologia Toracica
Talk: Interactive case presentation on immunotherapy
Milan, 01/Apr/2016

- 3rd Corso Multidisciplinare di Oncologia Polmonare
Title: Gestione terapeutica dei pazienti con mutazione di EGFR
Milan, 25-26/Feb/2016

- 2nd Lung Cancer Annual IEO Meeting
Title: La gestione del paziente con traslocazione di ALK dopo la prima linea
Milan, 20/Nov/2015

- Sharing experience in lung cancer
Talk: l'ottimizzazione del management terapeutico nei pazienti EGFR mutati
Rome, 23-25/Oct/2015

- ESPO: tumori polmonare dalle esperienze mondiali al nostro paziente. Cosa sta cambiando?
Talk: Immunotherapy in Lung Cancer
Milan, 06/Oct/2015

- Campus in Oncologia
Talk: strategie e gestione del paziente EGFR m+: dalla teoria alla pratica
Bologna, 25-26/Jun/2015

- The Young Biomarkers day: a SIF-AIOM joint symposium
Talk: Lung Cancer: the evolving role of biomarkers in NSCLC
Pisa, 15-16/May/2015

- 2nd Corso Multidisciplinare di Oncologia Polmonare
Talk: Gestione terapeutica dei pazienti con mutazione di EGFR
Milan, 26-27/Feb/2015
- AIOM: novità e criticità in Oncologia nel 2014
Talk: L'algoritmo terapeutico del tumore polmonare in fase avanzata
Milan, 28-29/Nov/2014
- 1st Lung Cancer Annual IEO Meeting
Talk: First-line of treatment in EGFR mut pts
Milan, 26/Nov/2014
- XVI Annual National Meeting AIOM (Italian Association of Medical Oncology)
Talk: Young Educational SR è disponibile dopo l'inizio della chemioterapia di prima linea: switch maintenance con EGFR TKIs?
Roma, 24-26/Oct/2014
- 34° Congresso Nazionale SICO (Italian Society Thoracic Surgery)
Talk: Oncologia Toracica: le novità terapeutiche
Naples, 2-4/Oct/2014
- Convegno Nazionale AIOM Giovani: 2014 News in Oncology
Talk: ALK Lung Cancer case presentation
Perugia, 11-12/Jul/2014
- 1st Corso Multidisciplinare di Oncologia Polmonare
Talk: Gestione terapeutica dei pazienti con mutazione di EGFR
Milan, 20/apr/2014
- Dall'aggiornamento clinico alla operatività gestionale nel setting avanzato del NSCLC
Talk: Criteri di selezione del paziente e sequenza terapeutica
Rome, 23/Nov/2013
- Convegno Nazionale AIOM Giovani: 2013 News In Oncology
Talk: Lung Cancer interactive discussion
Perugia, 5-6/Jul/2013
- MITHO - Master in Thoracic Oncology
Talk: Supportive Care and palliation of the most sign and symptoms in lung cancer,
Torino, 23/Mar/2013
- Lung Road Congress.
Talk: Bevacizumab and treatment in NSCLC.
Rome, 06/Jun/2011
- XIV Annual National Meeting AIOM (Italian Association of Medical Oncology)
Talk: Let's project together: giovani oncologi e progetti di ricerca in Italia e in Europa
Roma, 26/Oct/2012